CMS certification 143300
Ann & Robert H Lurie Childrens Hospital of Chicago
225 E Chicago Ave, Box 140, Chicago, IL 60611
This page brings together federal quality data for this hospital: its CMS star rating, patient survey results, emergency department times, and death, complication, infection and readmission rates, each compared with the national rate. Everything here comes from CMS and NPPES, the federal sources themselves - not from us.
What patients said
Answers from patients who stayed here, collected by CMS in the national HCAHPS survey: Oct 2024 – Sep 2025.
Not reported for this hospital
CMS had too few cases here to publish results for deaths, complications, infections caught in the hospital, readmissions and return visits. That is common at small, rural and specialty hospitals, and says nothing either way about quality.
Clinicians registered at this address
1,354 clinicians give this hospital's street address as their practice location in NPPES, the federal provider registry, plus 146 residents and trainees. The same address can take in offices and clinics in the building, and a listing does not prove admitting privileges or current employment.
| Specialty | Clinicians |
|---|---|
| Pediatrics | 348 |
| Nurse Practitioner | 63 |
| Pediatric Cardiology | 62 |
| Clinical | 45 |
| Pediatric Emergency Medicine | 44 |
| Genetic Counselor, MS | 38 |
| Pediatric Hematology-Oncology | 37 |
| Pediatric Critical Care Medicine | 33 |
| Physical Therapist | 30 |
| Neonatal-Perinatal Medicine | 28 |
| Neurology with Special Qualifications in Child Neurology | 28 |
| Pediatrics, Critical Care | 28 |
First 12 alphabetically
Money from drug and device companies
Drug and device makers have to report what they pay teaching hospitals to CMS's Open Payments program. At many teaching hospitals most of it is research funding, or royalties for inventions the hospital licensed to a company. A payment on its own does not show a conflict of interest.
- 2019 $6.6M
- 2020 $7.2M
- 2021 $4.3M
- 2022 $9.7M
- 2023 $6.2M
- 2024 $7.2M
- 2025 $5.2M
What the 2025 general payments were for
| Type of payment | Amount | Payments |
|---|---|---|
| Space rental and facility fees | $99,763 | 10 |
| Speaking, teaching and other services | $94,290 | 5 |
| Grants | $68,873 | 12 |
| Medical devices and supplies on long-term loan | $63,646 | 2 |
| Charitable contributions | $60,050 | 2 |
| Education | $4,216 | 2 |
| Debt forgiveness | $959 | 4 |
| Food and beverage | $138 | 1 |
Largest paying companies, 2025
| Company | Amount | Payments |
|---|---|---|
| Vertex Pharmaceuticals Incorporated | $422,654 | 8 |
| BioMarin Pharmaceutical Inc. | $355,425 | 55 |
| Amgen Inc. | $352,993 | 4 |
| Abbvie INC. | $349,701 | 46 |
| Biogen, Inc. | $308,112 | 5 |
| ACADIA Pharmaceuticals Inc | $256,259 | 11 |
| Merck Sharp & Dohme LLC | $203,588 | 7 |
| Sanofi US Services INC. | $186,265 | 11 |
Largest research studies funded here, 2025
| Study | Amount |
|---|---|
| ACP-101-302 ACADIA Pharmaceuticals Inc · NCT06173531 | $177,368 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO FOR THE TREATMENT OF OBESITY AND WEIGHT-RELATED COMORBIDITIES IN ADOLESCENTS: A RANDOMI… Eli Lilly and Company · NCT06439277 | $174,714 |
| A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 … Amgen Inc. | $170,612 |
| A Long-Term Extension Study of Nusinersen (BIIB058) Administered at Higher Doses in Participants With Spinal Muscular Atrophy Who Previously Particip… Biogen, Inc. | $166,304 |
| STUDY NAME#IMPAACT P1115, Very Early Intensive Treatment of HIV-Infected Infants to Achieve HIV Remission# A Phase I,II Proof of Concept Study Versi… Merck Sharp & Dohme LLC | $157,282 |
| An Open Label, Single Cohort Study to Assess the Pharmacokinetic Profile of Nusinersen (BIIB058) Administered Via the ThecaFlex DRx System (PIERRE-PK) Biogen, Inc. | $126,542 |
| A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging, Efficacy and Safety Study of SAR441566 Plus Methotrexate in Adults With Moderat… SANOFI US SERVICES INC. · NCT06073093 | $125,000 |
| A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 … Amgen Inc. | $122,382 |
Amounts are as the paying companies reported them to CMS; Open Payments data retrieved 13 Sep 2026. Full record on CMS Open Payments.
How to read this page
- Everything here is published by CMS on Care Compare. We arrange it and explain it; the star ratings and the better / worse verdicts are CMS's, not ours.
- “No different” is the most common result on most measures at most hospitals. CMS only calls a result better or worse when the difference from the national rate is statistically clear.
- Death, complication and readmission rates are adjusted by CMS for how sick patients were, so hospitals that treat sicker patients can be compared fairly.
- Infection results are ratios: 1.0 means as many infections as CMS predicted for a hospital like this one, below 1.0 is fewer.
- These are hospital-wide results. They do not rate an individual doctor, nurse or department, and they are not medical advice.
CMS Care Compare data retrieved 4 Oct 2026, refreshed weekly. Where this data comes from and how we handle it · Report an error
Common questions about Ann & Robert H Lurie Childrens Hospital of Chicago
Does Ann & Robert H Lurie Childrens Hospital of Chicago have an emergency room?
Yes. CMS lists emergency services at Ann & Robert H Lurie Childrens Hospital of Chicago.
Does Ann & Robert H Lurie Childrens Hospital of Chicago receive money from drug and device companies?
Drug and device makers reported $5.2M in payments to Ann & Robert H Lurie Childrens Hospital of Chicago for 2025, most of it research funding, under the federal Open Payments program. A payment on its own does not show a conflict of interest.